The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
Cost is a significant factor, admitted Matthew D. Harman, PharmD, MPH, especially since many payers felt burned by the price of Sovaldi the first time around. However, Ed Cohen, PharmD, FAPhA, said Walgreens stays neutral for of its payer clients and adheres to their formulary practices.
Steven Miller, MD, MBA, explained that since Harvoni and Viekira Pak seem to be equivalent in both use and outcome based on the studies, Express Scripts’ independent committee labelled both drugs as optional and let plans choose which one they wanted to add.
“Our national preferred formulary chose Viekira Pak, many of our other clients have chosen Harvoni,” he said. “We are fine with both and we have negotiated really great rates for all of our clients regardless of the products they’ve chosen.”
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen